(Q36429911)

14 August 2017

1 reference

title

Update in lung cancer 2005. (English)

1 reference

14 August 2017

James R Jett

1

1 reference

14 August 2017

York E Miller

series ordinal

2

1 reference

14 August 2017

language of work or name

English

0 references

publication date

1 April 2006

1 reference

American Journal of Respiratory and Critical Care Medicine

14 August 2017

published in

1 reference

14 August 2017

volume

173

1 reference

14 August 2017

issue

7

1 reference

14 August 2017

page(s)

695-697

1 reference

The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial

14 August 2017

cites work

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Familial lung cancer: genetic susceptibility and relationship to chronic obstructive pulmonary disease

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Risk of lung cancer among white and black relatives of individuals with early-onset lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Ethnic disparities in the treatment of stage I non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

EGFR mutations in lung cancer: correlation with clinical response to gefitinib therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Epidermal growth factor receptor gene and protein and gefitinib sensitivity in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Mutations in the epidermal growth factor receptor and in KRAS are predictive and prognostic indicators in patients with non-small-cell lung cancer treated with chemotherapy alone and in combination with erlotinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Epidermal growth factor receptor mutations and gene amplification in non-small-cell lung cancer: molecular analysis of the IDEAL/INTACT gefitinib trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Erlotinib in lung cancer - molecular and clinical predictors of outcome

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

EGFR mutation and resistance of non-small-cell lung cancer to gefitinib

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Lung adenocarcinoma global profiling identifies type II transforming growth factor-beta receptor as a repressor of invasiveness.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Measurement of hypoxia-related parameters in bronchial mucosa by use of optical spectroscopy

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Abnormalities in nitric oxide and its derivatives in lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Proteomic patterns of preinvasive bronchial lesions

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Immunotherapy of murine malignant mesothelioma using tumor lysate-pulsed dendritic cells

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

CD4+CD25+ regulatory T lymphocytes in malignant pleural effusion

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

CT screening for lung cancer: five-year prospective experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Early lung cancer detection using spiral computed tomography and positron emission tomography.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Diagnostic procedures after a positive spiral computed tomography lung carcinoma screen.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Guidelines for Management of Small Pulmonary Nodules Detected on CT Scans: A Statement from the Fleischner Society 1

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Etiology of solitary extrapulmonary positron emission tomography and computed tomography findings in patients with lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Detection of lung cancer by sensor array analyses of exhaled breath

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

3p microsatellite alterations in exhaled breath condensate from patients with non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Using protein microarray as a diagnostic assay for non-small cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Endobronchial and endoscopic ultrasound-guided real-time fine-needle aspiration for mediastinal staging.

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Morbidity and mortality in the surgery arm of EORTC 08941 trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Vinorelbine plus cisplatin vs. observation in resected non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Meta-analysis of postoperative adjuvant chemotherapy with tegafur-uracil in non-small-cell lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Gefitinib plus best supportive care in previously treated patients with refractory advanced non-small-cell lung cancer: results from a randomised, placebo-controlled, multicentre study (Iressa Survival Evaluation in Lung Cancer)

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

One hundred years of lung cancer

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

Pathogenesis of lung cancer: 100 year report

21 January 2018

1 reference

https://api.crossref.org/works/10.1164%2FRCCM.2601008

21 January 2018

Identifiers

DOI

10.1164/RCCM.2601008

1 reference

14 August 2017

1 reference